FGEN -18%/AH on_news_of_to-be-scheduled_adcomm_ for Roxadustat US NDA: https://www.globenewswire.com/news-release/2021/03/01/2184662/0/en/FibroGen-Provides-Regulatory-Update-on-Roxadustat.html FibroGen, Inc. and its partner, AstraZeneca today announced that the Cardiovascular and Renal Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) will hold an advisory committee (AdCom) meeting to review the new drug application for roxadustat in the U.S. The companies have not received a confirmed AdCom meeting date from the FDA. FGEN also reported 4Q20 financials (https://www.globenewswire.com/news-release/2021/03/01/2184671/0/en/FibroGen-Reports-Fourth-Quarter-and-Full-Year-2020-Financial-Results.html ).